Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit

Francesco Cucco,Sharon Barrans,Chulin Sha,Alexandra Clipson,Simon Crouch,Rachel Dobson,Zi Chen,Joe Sneath Thompson,Matthew A. Care,Thomas Cummin,Josh Caddy,Hongxiang Liu,Anne Robinson,Anna Schuh,Jude Fitzgibbon,Daniel Painter,Alexandra Smith,Eve Roman,Reuben Tooze,Catherine Burton,Andrew J. Davies,David R. Westhead,Peter W. M. Johnson,Ming-Qing Du
DOI: https://doi.org/10.1038/s41375-019-0691-6
2019-12-16
Leukemia
Abstract:Abstract Using a Burkitt lymphoma-like gene expression signature, we recently defined a high-risk molecular high-grade (MHG) group mainly within germinal centre B-cell like diffuse large B-cell lymphomas (GCB-DLBCL), which was enriched for MYC / BCL2 double-hit ( MYC / BCL2 -DH). The genetic basis underlying MHG-DLBCL and their aggressive clinical behaviour remain unknown. We investigated 697 cases of DLBCL, particularly those with MYC / BCL2 -DH ( n = 62) by targeted sequencing and gene expression profiling. We showed that DLBCL with MYC / BCL2 -DH, and those with BCL2 translocation, harbour the characteristic mutation signatures that are associated with follicular lymphoma and its high-grade transformation. We identified frequent MYC hotspot mutations that affect the phosphorylation site (T58) and its adjacent amino acids, which are important for MYC protein degradation. These MYC mutations were seen in a subset of cases with MYC translocation, but predominantly in those of MHG. The mutations were more frequent in double-hit lymphomas with IG as the MYC translocation partner, and were associated with higher MYC protein expression and poor patient survival. DLBCL with MYC / BCL2 -DH and those with BCL2 translocation alone are most likely derived from follicular lymphoma or its precursor lesion, and acquisition of MYC pathogenic mutations may augment MYC function, resulting in aggressive clinical behaviour.
oncology,hematology
What problem does this paper attempt to address?